Ondine’s Steriwave Shows Promise Against Deadly Mucor Fungus

Ondine Biomedical, Inc. ( (GB:OBI) ) just unveiled an announcement.

Ondine Biomedical Inc. has announced new data from University College London demonstrating the efficacy of its Steriwave photodisinfection technology against the Mucor fungus, a serious threat to immunocompromised patients. The findings, presented at the 19th World Congress of the International Photodynamic Association, highlight Steriwave’s potential to significantly reduce healthcare-associated infections by effectively decolonizing nasal passages of fungal pathogens, offering a promising new approach to infection prevention in hospital settings.

The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

More about Ondine Biomedical, Inc.

Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those caused by multidrug-resistant organisms. The company has a range of investigational products based on its proprietary technology, with its nasal photodisinfection system, Steriwave, approved in several countries and undergoing clinical trials in the US.

Average Trading Volume: 140,110

Technical Sentiment Signal: Sell

Current Market Cap: £39.89M

Find detailed analytics on OBI stock on TipRanks’ Stock Analysis page.